Characteristics and Treatment Patterns of Patients with Haemophilia B Receiving Recombinant Coagulation Factor IX
Authors:
- Young-Shil ParkYPYoung-Shil Park
- Tai Ju HwangTHTai Ju Hwang
- Sang Kyu ParkSPSang Kyu Park
- Eun Jin ChoiECEun Jin Choi
- Jeong A ParkJeong A Park
- Hee Jo BaekHBHee Jo Baek
- Chuhl Joo LyuCLChuhl Joo Lyu
- Jae Hee LeeJLJae Hee Lee
- Mi Kyung KimMKMi Kyung Kim
- Ji Yoon KimJKJi Yoon Kim
- Sun Ah LeeSLSun Ah Lee
- Boram ParkBPBoram Park
Open Access
- 26 June 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4555
Abstract
Introduction: In Haemophilia B, guideline-level factor IX (FIX) prophylaxis is recommended, but real-world dosing and adherence vary. Aim: To assess treatment patterns, adherence, FIX dosing, and their associations with bleeding events in Korean patients. Methods: We conducted a retrospective chart review and one-time survey of 130 Korean patients with haemophilia B treated with FIX for ≥12 months at 12 centers (June 2022–May 2023). A total of forty-seven patients (36.2%) received prophylaxis (≥90 IU/kg/week for ≥45 weeks); the remainder were managed non-prophylactically. Annualized bleeding events (ABEs) were analyzed using negative binomial regression, and monthly bleeds with a generalized linear mixed model. Covariates with p < 0.10 and clinical relevance were included in multivariable models. Results: The prophylaxis group showed significantly fewer ABEs (incidence rate ratio [IRR]: 0.383, p = 0.011). Each 100 IU/kg monthly dose increment reduced bleed risk (IRR: 0.692, p < 0.001). Adherence showed no independent association with bleeding in adjusted models. Conclusions: Bleed prevention in haemophilia B is driven more by delivered FIX exposure than by regimen label. Study-defined sustained prophylaxis remains underused and under-dosed. Individualized dosing and continuous adherence monitoring are essential to close this treatment gap and improve outcomes.Keywords
Funding Information
- Pfizer (X9001303)
This publication has 25 references indexed in Scilit:
- International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodologyJournal of Thrombosis and Haemostasis, 2024
- Hemophilia B (Factor IX Deficiency)Hematology/Oncology Clinics of North America, 2021
- The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United StatesAmerican Journal of Hematology, 2020
- Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis StudyResearch and Practice in Thrombosis and Haemostasis, 2020
- The benefits of prophylaxis in patients with hemophilia BExpert Review of Hematology, 2018
- Prophylaxis use among males with haemophilia B in the United StatesHaemophilia, 2017
- Recent advances in hemophilia B therapyDrug Delivery and Translational Research, 2017
- Once‐weekly prophylactic treatment vs. on‐demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia BHaemophilia, 2016
- Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjectsHaemophilia, 2014
- Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic reviewHaemophilia, 2013